CME Group CME Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 65.6%+0.7pp | 64.9%-0.1pp | 65%-0.3pp | 65.3%+0.4pp | 64.9%+0.8pp | |
| Net margin | 63.6%+1.1pp | 62.5%+3.7pp | 58.8%+0.4pp | 58.4%+0.7pp | 57.7%+0.2pp | |
| Returns | ||||||
| Return on equity | 16%+1.3pp | 14.8%+1.4pp | 13.3%-0.3pp | 13.6%+0.2pp | 13.4%+0.1pp | |
| Return on invested capital | 15.4%+0.2pp | 15.2%+1.2pp | 14%-0.2pp | 14.2%+0.4pp | 13.8%-0.4pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 1×0.0× | 1×0.0× | 1×0.0× | 1×0.0× | 1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | 0.3×+0.4× | -0.2×-0.5× | 0.3×-0.1× | 0.4×-0.2× | 0.6×+0.3× | |
| Per Share | ||||||
| Book value per share | $73.29-8.1% | $79.73+1.9% | $78.21+1.6% | $76.98+2.6% | $75.04+2.0% | |
| Valuation | ||||||
| Market capitalization | $86.61B-14.9% | $98.47B+1.1% | $97.37B-0.4% | $97.79B+2.3% | $95.61B+14.2% | |
| Price / earnings | 20.2×-6.9× | 24.2×-1.7× | 25.9×-0.1× | 26×-0.4× | 26.4×+2.6× | |
| Price / sales | 12.8×-3.0× | 15.1×-0.1× | 15.2×0.0× | 15.2×0.0× | 15.2×+1.6× | |
| Price / book | 3.3×-0.4× | 3.4×0.0× | 3.5×-0.1× | 3.5×0.0× | 3.5×+0.4× | |
| EV / EBITDA | 19.1×-4.8× | 22.6×-0.6× | 23.1×+0.1× | 23.1×-0.3× | 23.4×+2.5× | |
| Dividend yield | 4.7%+0.9pp | 4%0.0pp | 4%+0.1pp | 3.9%-0.1pp | 4%-0.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do CME Group's ratios come from?
- Every ratio is computed from CME Group's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
